*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2026 | Growth hormone releasing peptide-6 (GHRP-6) ameliorates acute lung injury and its subsequent evolvement to interstitial fibrosis International immunopharmacology · preclinical | PMID 41534456 |
| 2025 | Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation Journal of nanobiotechnology · preclinical | PMID 41327290 |
| 2024 | Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms Frontiers in pharmacology · preclinical | PMID 38873418 |
| 2015 | [D-Lys3]-GHRP-6 exhibits pro-autophagic effects on skeletal muscle Molecular and cellular endocrinology · preclinical | PMID 25450862 |
| 2015 | Detection of GHRP-2 and GHRP-6 in urine samples from athletes Drug testing and analysis · preclinical | PMID 25809000 |
| 2015 | Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin Drug testing and analysis · preclinical | PMID 25869809 |
| 2014 | N-aminoimidazolidin-2-one peptidomimetics Organic letters · preclinical | PMID 24697286 |
| 2010 | GHRP-6 induces CREB phosphorylation and growth hormone secretion via a protein kinase Csigma-dependent pathway in GH3 cells Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · preclinical | PMID 20407870 |
| 2006 | Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure Clinical science (London, England : 1979) · preclinical | PMID 16417467 |
| 1996 | Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency Journal of pediatric endocrinology & metabolism : JPEM · preclinical | PMID 8887178 |
| 1996 | Growth hormone response to GHRH, GHRP-6 and GHRH + GHRP-6 in patients with polycystic ovary syndrome Clinical endocrinology · preclinical | PMID 8959075 |
| 1995 | Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood Clinical endocrinology · human | PMID 7734029 |
GHRP-6 (Growth Hormone-Releasing Peptide-6). Synthetic GH secretagogue (GHS-R agonist). Strong GH release plus pronounced appetite stimulation; moderate cortisol/prolactin effect.
Commonly discussed uses: GH-axis research, appetite-stimulation research. There is both human and animal/preclinical research, though the depth and quality vary by indication. Note: most uses are not approved indications.
Mechanism: Synthetic GH secretagogue (GHS-R agonist). Strong GH release plus pronounced appetite stimulation; moderate cortisol/prolactin effect.
Reported considerations: marked hunger, cortisol/prolactin rise, water retention, head-rush, tingling. There is both human and animal/preclinical research, though the depth and quality vary by indication. WADA-prohibited. Not approved for human therapeutic use. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low 100mcg, typical 100-300mcg 1-3x/day, high 300mcg 3x/day. Administration: subcutaneous. Half-life: ~15-60 min.
Australian status: Not ARTG-registered; research; WADA prohibited. WADA-prohibited. Not approved for human therapeutic use. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: 2ml BAC water per 5mg vial; storage: refrigerated.
Commonly discussed combinations (anecdotal for unapproved compounds): GHRP-6 + CJC-1295 (anecdotal). Stacking increases interaction/safety uncertainty.